The Neurocognitive Profile: A High Efficiency Integrated Brain-Behavior Assay

描述（由申请人提供）： 神经认知功能的改变在许多睡眠、神经和精神疾病中起着重要作用，并可能对生活质量、治疗效果、康复以及工作和正常日常活动中的功能能力产生重大影响。目前可用于神经认知研究的方法，包括传统的神经心理学评估（例如Halstead-Reitan，Wechsler记忆电池），神经生理学测量（例如脑电图，多次睡眠潜伏期测试）和行为测试（例如连续性能测试，精神警觉性测试）是耗时，昂贵的，并且通常需要大量的技术专长来管理和解释。警觉性和记忆分析（AMP）系统将神经生理学、行为和主观测量集成在一个平台中，该平台旨在对神经认知功能进行定量评估，包括警觉性、注意力、学习和记忆。AMP采用多变量方法，将EEG、神经心理学测试和经验证的自我报告清单结合在一套易于管理的方案中。初步研究显示，AMP可用于表征健康受试者与睡眠剥夺相关的警觉性，学习和记忆的变化，并提供一种生物行为测定， 最容易和最不容易受到睡眠剥夺影响的个体。AMP在区分患有高度流行的、诊断不足的阻塞性睡眠呼吸暂停（OSA）的患者和健康受试者方面也被证明是敏感和特异的。AMP表征了个体的警觉性和记忆障碍，并量化了CPAP治疗后某些认知障碍的改善。四个神经认知因素来自AMP数据：持续注意，加工速度，言语记忆和视觉空间记忆。 AMP原型系统的初步调查，导致了广泛的研究人员和临床医生有兴趣将AMP应用于睡眠医学，药物成瘾，药物评价，法医调查，人体工程学，运动医学，军事应用，教育/培训评估和职业医学的调查。第一阶段的计划是在睡眠医学领域工作的基础上，扩展AMP平台的开发，以适应潜在应用的范围，并与纽约大学睡眠实验室合作，在临床应用研究中迈出AMP产品发展的下一步。

DESCRIPTION (provided by applicant): Alterations in neurocognitive function play a major role in numerous sleeps, neurological and psychiatric disorders and can have a significant impact on quality of life, treatment efficacy, rehabilitation and ability to function at work and in normal daily activities. The methods currently available for neurocognitive investigations including traditional neuropsychological assessment (e.g. Halstead-Reitan, Wechsler memory battery), neurophysiological measures (e.g. electroencephalogram, Multiple Sleep Latency Test) and behavioral tests (e.g. Continuous Performance Test, Psychomotor Vigilance Test) are time-consuming, expensive and often require substantial technical expertise to administer and interpret. The Alertness and Memory Profiling (AMP) system integrates neurophysiological, behavioral and subjective measures in a platform designed for quantitative assessment of neurocognitive functions including alertness, attention, learning and memory. The AMP employs a multivariate approach, combining EEG, neuropsychological tests and validated self-report inventories in an easy-to-administer set of protocols. Initial investigations revealed that AMP could be used to characterize the changes in alertness, learning and memory associated with sleep deprivation in healthy subjects and to provide a biobehavioral assay that identified those Individuals most and least susceptible to the effects of sleep deprivation. The AMP also proved sensitive and specific in discriminating patients with the highly prevalent, under-diagnosed Obstructive Sleep Apnea (OSA) from healthy subjects. The AMP characterized individual profiles of alertness and memory impairment and quantified the amelioration of some cognitive impairments following treatment with CPAP. Four neurocognitive factors were derived from the AMP data: sustained attention, processing speed, verbal memory and visuospatial memory. Preliminary investigations with the AMP prototype systems have resulted in inquiries from a wide range of researchers and clinicians interested in applying the AMP to investigations in sleep medicine, drug addiction, pharmaceutical evaluation, forensic investigations, ergonomics, sports medicine, military applications, education/training evaluations, and occupational medicine. The plan for the Phase I is to build upon this foundation of work in the area of sleep medicine, and extend the development of AMP platform to accommodate the range of potential applications and to take the next step in the evolution of the AMP product in a clinical applications study in collaboration with the New York University sleep laboratory.